Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- Citation:
- J Clin Oncol vol 32 (33) 3744-3752
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Meta-Analysis
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 4
- Parents:
- 703
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882 , UG1 CA189867, U10 CA012027, U10 CA180821, U10 CA069651, P30 CA015083, U10 CA180882, R01 CA129949, U10 CA069974, U10 CA025224, U10 CA180888, U10 CA037377
- Corr. Author:
- Authors:
- Edith A. Perez Edward H. Romond Vera J. Suman Jong-Hyeon Jeong George Sledge Charles E. Geyer Silvana Martino Priya Rastogi Julie Gralow Sandra M. Swain Eric P. Winer Gerardo Colon-Otero Nancy E. Davidson Eleftherios Mamounas Jo Anne Zujewski Norman Wolmark
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Bc5, ORIGINAL REPORTS, Breast Cancer